Fig. 3: Combined incidence and severity of IRR- and CRS-related adverse events and associated symptoms. | Nature Communications

Fig. 3: Combined incidence and severity of IRR- and CRS-related adverse events and associated symptoms.

From: CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

Fig. 3

Data for (a) ADA-negative and (b) ADA-positive patients are shown by infusion for patients receiving 40–600 mg of cibisatamab (flat-dose and step-up dosing cohorts) in S1 and S2. ADA, Anti-drug antibody; CRS, Cytokine-release syndrome; IRR, Infusion-related reaction; M Grade information not provided by site. Source data can be requested from the authors for academic research purposes.

Back to article page